1-7 of 7
Alice Loo
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 4026: JDQ443, a covalent inhibitor of KRASG12C with a novel binding mode, shows broad antitumor activity in KRASG12C preclinical models as a single agent and in combination with inhibitors of SHP2, MEK or CDK4/6

Andreas Weiss, Hans Voshol, Diana Graus Porta, Carmine Fedele, Dario Sterker, Ruben De Kanter, Rowan Stringer, Toni Widmer, Alice Loo, Daniel A. Guthy, Kim S. Beyer, Nils Ostermann, Catherine LeBlanc, Marc Gerspacher, Andrea Vaupel, Richard Sedrani, Frederic Zecri, Saveur-Michel Maria, Francesco Hofmann, Peter Hammerman, Jeff Engelman, Edwige Lorthiois, Simona Cotesta, Saskia M. Brachmann
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 4026.
https://doi.org/10.1158/1538-7445.AM2022-4026
Published: 15 June 2022
View article titled, Abstract 4026: JDQ443, a covalent inhibitor of KRAS<sup>G12C</sup> with a novel binding mode, shows broad antitumor activity in KRAS<sup>G12C</sup> preclinical models as a single agent and in combination with inhibitors of SHP2, MEK or CDK4/6
Journal Articles

A Proof of Concept for Biomarker-Guided Targeted Therapy against Ovarian Cancer Based on Patient-Derived Tumor Xenografts

Adam C. Palmer, Deborah Plana, Hui Gao, Joshua M. Korn, Guizhi Yang, John Green, Xiamei Zhang, Roberto Velazquez, Margaret E. McLaughlin, David A. Ruddy, Colleen Kowal, Julie Muszynski, Caroline Bullock, Stacy Rivera, Daniel P. Rakiec, GiNell Elliott, Paul Fordjour, Ronald Meyer, Alice Loo, Esther Kurth, Jeffrey A. Engelman, Hans Bitter, William R. Sellers, Juliet A. Williams, Peter K. Sorger
Journal: Cancer Research
Cancer Res (2020) 80 (19): 4278–4287.
https://doi.org/10.1158/0008-5472.CAN-19-3850
Published: 02 October 2020
View article titled, A Proof of Concept for Biomarker-Guided Targeted Therapy against Ovarian Cancer Based on Patient-Derived Tumor Xenografts
Open the PDF for A Proof of Concept for Biomarker-Guided Targeted Therapy against Ovarian Cancer Based on Patient-Derived Tumor Xenografts in another window
Includes: Supplementary data
Journal Articles

Abstract 922: Preclinical anticancer activity of LSZ102, a novel oral selective estrogen receptor degrader targeting wild-type and mutant ER

L. Alex Gaither, Choi Lai Tiong Yip, Chunrong Wang, Weiyi Toy, Qing Sheng, Jinyun Chen, Yuji Mishina, Rita Das, Stefan Peukert, Alice Loo, Sarat Chandarlapaty, Adam Crystal, Tinya J. Abrams
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 922.
https://doi.org/10.1158/1538-7445.AM2019-922
Published: 01 July 2019
View article titled, Abstract 922: Preclinical anticancer activity of LSZ102, a novel oral selective estrogen receptor degrader targeting wild-type and mutant ER
Journal Articles

Abstract 682: Identification of HSP90 inhibitor sensitizers through pooled RNA interference screen

Yaoyu Chen, Jinyun Chen, Alice Loo, Margaret Mclaughlin, Raymond Pagliarini, Wenlai Zhou
Journal: Cancer Research
Cancer Res (2014) 74 (19_Supplement): 682.
https://doi.org/10.1158/1538-7445.AM2014-682
Published: 01 October 2014
View article titled, Abstract 682: Identification of HSP90 inhibitor sensitizers through pooled RNA interference screen
Journal Articles

Protein Kinase C Inhibitor Sotrastaurin Selectively Inhibits the Growth of CD79 Mutant Diffuse Large B-Cell Lymphomas

Tara L. Naylor, Huaping Tang, Boris A. Ratsch, Andreas Enns, Alice Loo, Liqing Chen, Peter Lenz, Nigel J. Waters, Walter Schuler, Bernd Dörken, Yung-mae Yao, Markus Warmuth, Georg Lenz, Frank Stegmeier
Journal: Cancer Research
Cancer Res (2011) 71 (7): 2643–2653.
https://doi.org/10.1158/0008-5472.CAN-10-2525
Published: 31 March 2011
View article titled, Protein Kinase C Inhibitor Sotrastaurin Selectively Inhibits the Growth of CD79 Mutant Diffuse Large B-Cell Lymphomas
Open the PDF for Protein Kinase C Inhibitor Sotrastaurin Selectively Inhibits the Growth of CD79 Mutant Diffuse Large B-Cell Lymphomas in another window
Includes: Supplementary data
Journal Articles

The Polycomb Group Protein Bmi-1 Is Essential for the Growth of Multiple Myeloma Cells

Zainab Jagani, Dmitri Wiederschain, Alice Loo, Dan He, Rebecca Mosher, Paul Fordjour, John Monahan, Michael Morrissey, Yung-Mae Yao, Christoph Lengauer, Markus Warmuth, William R. Sellers, Marion Dorsch
Journal: Cancer Research
Cancer Res (2010) 70 (13): 5528–5538.
https://doi.org/10.1158/0008-5472.CAN-09-4229
Published: 30 June 2010
View article titled, The Polycomb Group Protein Bmi-1 Is Essential for the Growth of Multiple Myeloma Cells
Open the PDF for The Polycomb Group Protein Bmi-1 Is Essential for the Growth of Multiple Myeloma Cells in another window
Includes: Supplementary data
Journal Articles

PI3K Pathway Activation Mediates Resistance to MEK Inhibitors in KRAS Mutant Cancers

Susan Wee, Zainab Jagani, Kay Xiaoqin Xiang, Alice Loo, Marion Dorsch, Yung-Mae Yao, William R. Sellers, Christoph Lengauer, Frank Stegmeier
Journal: Cancer Research
Cancer Res (2009) 69 (10): 4286–4293.
https://doi.org/10.1158/0008-5472.CAN-08-4765
Published: 15 May 2009
View article titled, PI3K Pathway Activation Mediates Resistance to MEK Inhibitors in KRAS Mutant Cancers
Open the PDF for PI3K Pathway Activation Mediates Resistance to MEK Inhibitors in KRAS Mutant Cancers in another window
Includes: Supplementary data